Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ondansetron

FDA-approved product (tablet, orally disintegrating, oral), marketed as Ondansetron, Zofran Odt, Zuplenz and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ondansetron
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Radiation-induced nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Serotonin (5ht3) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ondansetron in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ondansetron with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ondansetron's Opposite Effect on Postoperative Analgesia of Acetaminophen

    NCT02296333 · start 2014-05

    Registered record
    Registry ID
    NCT02296333
    Conditions
    Postoperative Pain
    Interventions
    ondansetron; isotonic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    Interventionondansetron; isotonic
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Procedural Analgesia for Liposonix Treatment

    NCT01993238 · start 2013-11

    Registered record
    Registry ID
    NCT01993238
    Conditions
    Body Contouring
    Interventions
    Liposonix System (Model 2); Pre-treatment analgesia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Contouring
    InterventionLiposonix System (Model 2); Pre-treatment analgesia
    PhaseNot applicable
    Registry statusCompleted

  • Improving Tolerance of Treatment of Pulmonary MAC Infections

    NCT01719042 · start 2013-01

    Registered record
    Registry ID
    NCT01719042
    Conditions
    Mycobacterium Avium Complex; Adverse Effects
    Interventions
    Zofran (8mg); Ensure
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2013-01
    Completion
    2013-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium Complex; Adverse Effects
    InterventionZofran (8mg); Ensure
    PhasePhase 2
    Registry statusWithdrawn

  • How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

    NCT01801475 · start 2013-01

    Registered record
    Registry ID
    NCT01801475
    Conditions
    Postoperative Nausea
    Interventions
    Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea
    InterventionOndansetron
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

    NCT01592708 · start 2012-06

    Registered record
    Registry ID
    NCT01592708
    Conditions
    Post-operative Nausea; Post-operative Vomiting; Nausea Persistent
    Interventions
    Antiemetic anesthesia protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-04
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-operative Nausea; Post-operative Vomiting; Nausea Persistent
    InterventionAntiemetic anesthesia protocol
    PhaseNot applicable
    Registry statusCompleted

  • Prevention of Postoperative Nausea and Vomiting

    NCT02382146 · start 2012-04

    Registered record
    Registry ID
    NCT02382146
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    dexamethasone ondansetron; Dexamethasone dimenhidrinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    Interventiondexamethasone ondansetron; Dexamethasone dimenhidrinate
    PhasePhase 4
    Registry statusCompleted

  • Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients

    NCT01370408 · start 2012-02

    Registered record
    Registry ID
    NCT01370408
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Palonosetron; ondansetron; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-02
    Completion
    2016-03
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionPalonosetron; ondansetron; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

    NCT01572012 · start 2012-02

    Registered record
    Registry ID
    NCT01572012
    Conditions
    Healthy
    Interventions
    Ondansetron; Ondansetron + Hylenex; Zofran ODT; Ondansetron solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOndansetron; Ondansetron + Hylenex; Zofran ODT; Ondansetron solution
    PhasePhase 1
    Registry statusCompleted

  • The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department

    NCT01477242 · start 2011-11

    Registered record
    Registry ID
    NCT01477242
    Conditions
    Sedation and Analgesia; Side Effect of Drug
    Interventions
    Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2011-11
    Completion
    2012-05
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSedation and Analgesia; Side Effect of Drug
    InterventionOndansetron
    PhaseNot applicable
    Registry statusUnknown

  • Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

    NCT01536691 · start 2011-06

    Registered record
    Registry ID
    NCT01536691
    Conditions
    Cancer; Malignancy
    Interventions
    ramosetron; ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-06
    Completion
    2013-02
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Malignancy
    Interventionramosetron; ondansetron
    PhasePhase 3
    Registry statusUnknown

  • Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

    NCT01298193 · start 2011-05

    Registered record
    Registry ID
    NCT01298193
    Conditions
    Breast Cancer
    Interventions
    Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2014-04
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAprepitant
    PhasePhase 4
    Registry statusCompleted

  • Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

    NCT01346267 · start 2011-05

    Registered record
    Registry ID
    NCT01346267
    Conditions
    Central Nervous System Tumor, Pediatric; Chemotherapy-induced Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    Real Acupressure Band; Placebo Acupressure Band
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-05
    Completion
    2016-05
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Nervous System Tumor, Pediatric; Chemotherapy-induced Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
    InterventionReal Acupressure Band; Placebo Acupressure Band
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition

    NCT01578252 · start 2011-05

    Registered record
    Registry ID
    NCT01578252
    Conditions
    Fasting State
    Interventions
    Ondansetron Tablets USP 8 mg; Ondansetron Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-09
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFasting State
    InterventionOndansetron Tablets USP 8 mg; Ondansetron Hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • New Treatment Option for Pancreatic Cancer

    NCT01364805 · start 2011-04

    Registered record
    Registry ID
    NCT01364805
    Conditions
    Pancreatic Cancer
    Interventions
    Intravenous Vitamin C; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2015-10
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionIntravenous Vitamin C; Gemcitabine
    PhasePhase 1
    Registry statusCompleted

  • Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

    NCT01640340 · start 2011-01

    Registered record
    Registry ID
    NCT01640340
    Conditions
    Malignant Neoplasm
    Interventions
    aprepitant; palonosetron hydrochloride; ondansetron; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    Interventionaprepitant; palonosetron hydrochloride; ondansetron; dexamethasone
    PhaseNot applicable
    Registry statusCompleted